Definium Therapeutics (DFTX) Other Non Operating Income (2021 - 2026)
Definium Therapeutics (DFTX) posted quarterly Other Non Operating Income of -$17.9 million for Q1 2026, down 93994.74% year-over-year from N/an in Q1 2025, and down 45741.03% quarter-over-quarter from -$39000.0 in Q3 2025.
Powered by 
Analysis
Definium Therapeutics (DFTX) Other Non Operating Income (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Other Non Operating Income for 6 consecutive years, with -$17.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 93994.74% year-over-year to -$17.9 million; the TTM figure through Mar 2026 stood at -$19.8 million (down 245.48% YoY), while the FY2024 annual figure was -$638000.0, changed N/A from the prior year.
- Other Non Operating Income eased to -$17.9 million in Q1 2026 per DFTX's latest filing, from -$39000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $11.1 million in Q3 2024 and bottomed at -$32.2 million in Q1 2024.
- Historically, Other Non Operating Income has averaged -$2.7 million across 5 years, with a median of -$29000.0 in 2025.
- Annual changes were most pronounced in 2024 — Other Non Operating Income jumped 4605.56% — and 2026, when it slumped 93994.74%.
- Definium Therapeutics' Other Non Operating Income stood at -$343000.0 in 2022, then surged by 171.14% to $244000.0 in 2023, then slumped by 120.08% to -$49000.0 in 2024, then advanced by 20.41% to -$39000.0 in 2025, then sank by 45741.03% to -$17.9 million in 2026.
- Business Quant data shows DFTX's Other Non Operating Income at -$17.9 million in Q1 2026, -$39000.0 in Q3 2025, and -$1.8 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Definium Therapeutics | 4.24 Bn | 4.24 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -83.91 Mn |
| Mar 31, 2026 | -17.88 Mn |
| Dec 31, 2025 | -2.86 Mn |
| Sep 30, 2025 | -21.60 Mn |
| Jun 30, 2025 | -1.84 Mn |
| Mar 31, 2025 | 8.81 Mn |
| Dec 31, 2024 | -7.30 Mn |
| Sep 30, 2024 | 11.11 Mn |
| Jun 30, 2024 | 18.60 Mn |
| Mar 31, 2024 | -32.20 Mn |
| Dec 31, 2023 | -1.62 Mn |
| Sep 30, 2023 | 3.69 Mn |
| Jun 30, 2023 | 247,000.00 |
| Mar 31, 2023 | -3.95 Mn |
| Dec 31, 2022 | 9.00 Mn |
| Sep 30, 2022 | 498,000.00 |
| Jun 30, 2022 | -89,000.00 |
| Mar 31, 2022 | 54,000.00 |
| Dec 31, 2021 | -12.71 Mn |
| Sep 30, 2021 | -40,000.00 |